Monthly Archives: November 2012
FDA approves Regeneron’s Eylea for CRVO
Regeneron announced via press release that the U.S. Food and Drug Administration has approved Eylea intravitreal injection for macular edema after central retinal vein occlusion. This is the FDA’s second approved indication for Eylea (aflibercept). The drug was approved for intravitreal injection for the treatment of neovascular age-related macular degeneration in November 2011. Aflibercept consists… Read More
Can E-readers Help Your Macular Disease Patients?
Easier reading for those with visual deficits June 2011 Current treatments for macular disease are leading to gratifying results, saving much of the severe vision loss that was often unavoidable 10 years ago. Still, despite optimal treatment, many patients end up with a moderate level of visual impairment and complain of difficulty in accessing the… Read More